Literature DB >> 13934700

The saga of thalidomide. Neuropathy to embryopathy, with case reports of congenital anomalies.

G W MELLIN, M KATZENSTEIN.   

Abstract

Entities:  

Keywords:  ABNORMALITIES; NEUROLOGY; THALIDOMIDE

Mesh：

Substances：

Year:  1962        PMID： 13934700     DOI： 10.1056/NEJM196212132672407

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  16 in total

1.  The Need for Pediatric Drug Development.

Authors:  Robert M Ward; Daniel K Benjamin; Jonathan M Davis; Richard L Gorman; Ralph Kauffman; Gregory L Kearns; Mary Dianne Murphy; Catherine M T Sherwin
Journal:  J Pediatr       Date:  2017-09-21       Impact factor: 4.406

2.  Thalidomide--the way forward.

Authors:  J M Gardner-Medwin; R J Powell
Journal:  Postgrad Med J       Date:  1994-12       Impact factor: 2.401

3.  Docetaxel and thalidomide as a treatment option for androgen- independent, nonmetastatic prostate cancer.

Authors:  Gregory D Leonard; William L Dahut; James L Gulley; Philip M Arlen; William D Figg
Journal:  Rev Urol       Date:  2003

4.  Drug target-gene signatures that predict teratogenicity are enriched for developmentally related genes.

Authors:  Asher D Schachter; Isaac S Kohane
Journal:  Reprod Toxicol       Date:  2010-11-27       Impact factor: 3.143

Review 5.  Modern management of the cancer anorexia-cachexia syndrome.

Authors:  K A Nelson
Journal:  Curr Oncol Rep       Date:  2000-07       Impact factor: 5.075

Review 6.  Angiogenesis inhibitors in the treatment of prostate cancer.

Authors:  Paul G Kluetz; William D Figg; William L Dahut
Journal:  Expert Opin Pharmacother       Date:  2010-02       Impact factor: 3.889

7.  Use of thalidomide to diminish growth velocity in a life-threatening congenital intracranial hemangioma.

Authors:  Melissa Frei-Jones; Robert C McKinstry; Arie Perry; Jeffrey R Leonard; Tae Sung Park; Joshua B Rubin
Journal:  J Neurosurg Pediatr       Date:  2008-08       Impact factor: 2.375

8.  A phase II study of thalidomide in advanced metastatic renal cell carcinoma.

Authors:  David R Minor; Dana Monroe; Lisa A Damico; Gloria Meng; Uma Suryadevara; Laurence Elias
Journal:  Invest New Drugs       Date:  2002-11       Impact factor: 3.850

9.  The rise, fall and subsequent triumph of thalidomide: lessons learned in drug development.

Authors:  Waqas Rehman; Lisa M Arfons; Hillard M Lazarus
Journal:  Ther Adv Hematol       Date:  2011-10

10.  Immunomodulatory drugs disrupt the cereblon-CD147-MCT1 axis to exert antitumor activity and teratogenicity.

Authors:  Ruth Eichner; Michael Heider; Vanesa Fernández-Sáiz; Frauke van Bebber; Anne-Kathrin Garz; Simone Lemeer; Martina Rudelius; Bianca-Sabrina Targosz; Laura Jacobs; Anna-Maria Knorn; Jolanta Slawska; Uwe Platzbecker; Ulrich Germing; Christian Langer; Stefan Knop; Herrmann Einsele; Christian Peschel; Christian Haass; Ulrich Keller; Bettina Schmid; Katharina S Götze; Bernhard Kuster; Florian Bassermann
Journal:  Nat Med       Date:  2016-06-13       Impact factor: 53.440
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.